Growth Factor News and Research

RSS

Suppression of growth hormone and related compounds beginning in early adulthood may delay the onset or progression of several types of cancer

A modest suppression of growth hormone and related compounds beginning in early adulthood may delay the onset or progression of several types of cancer, researchers from Wake Forest University School of Medicine and other centers reported today at ENDO 2005, the annual meeting of the Endocrine Society, in San Diego.

5 Jun 2005

Chemo combo increases breast cancer survival

A new Spanish study has found that a combination of chemotherapy drugs can increase the five-year survival rate of women with metastatic, node-positive breast cancer by 7 percent.

2 Jun 2005

New approach to inhibiting blood vessel growth or angiogenesis

A manmade protein with a tail of amino acids delivered to target cells can dramatically reduce blood vessel growth that obstructs vision or feeds a tumor, researchers have found.

31 May 2005

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

"Even in people who have gone through six or more previous courses of chemotherapy, cetuximab, may fight the growth of cancer, giving patients additional months of life," says study presenter Heinz-Josef Lenz, M.D., associate professor of medicine at the Keck School of Medicine of the University of Southern California and USC/Norris Comprehensive Cancer Center.

20 May 2005

New drug combination prevents breast cancer growth pre-surgery

A new type of drug originally developed for lung cancer can reduce the size of breast cancer tumours when taken in combination with other drugs.

17 May 2005

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Giving women with early breast cancer a drug called gefitinib (Iressa) before surgery could reduce the size of their tumours, suggests a randomised trial published online today by The Lancet Oncology.

17 May 2005

Engineers have found a way to modify a plastic to anchor molecules that promote nerve regeneration, blood vessel growth or other biological processes

In the study led by Dr. Christine Schmidt, the researchers identified a piece of protein from among a billion candidates that could perform the unusual feat of attaching to polypyrrole, a synthetic polymer (plastic) that conducts electricity and has shown promise in biomedical applications.

17 May 2005

SU11248 drug show promise against neuroendocrine tumors-stubborn cancers that respond poorly to chemotherapy

A unique, targeted anti-cancer drug appears to show promise against neuroendocrine tumors-stubborn cancers that have traditionally responded poorly to chemotherapy, according to research findings announced at the 2005 Annual Meeting of the American Society of Clinical Oncology (ASCO).

17 May 2005

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

A targeted cancer drug given with low-dose chemotherapy shrank ovarian tumors and slowed progression of ovarian cancer in patients with recurrent disease, according to research findings presented by Agustin Garcia, M.D., principal investigator of the study and Director of Breast Cancer Research at the Women's Cancer Research Institute at the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai Medical Center.

16 May 2005

Moderate recreational and work-related physical activity may reduce the risk of ovarian cancer

While the benefits of physical activity in reducing colon and breast cancer are well established, results of studies on exercise and ovarian cancer have been inconclusive. Because ovarian cancer has such a poor prognosis, it is even more important to identify modifiable lifestyle factors that could prevent it.

16 May 2005

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

Patients with a particular type of advanced lung cancer may have a new option based on data presented at the 2005 annual meeting of the American Society of Clinical Oncology showing that combining a drug that cuts off the cancer's blood supply with standard chemotherapy can shrink tumors and extend life.

15 May 2005

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Recent studies of a new anticancer drug show continued response for patients with late-stage kidney cancer. Robert Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center (MSKCC), reported a response rate of 40 percent in patients with metastatic (advanced) renal cell (kidney) cancer who received SU11248 in second-line therapy.

15 May 2005

Vitamin A's paradoxical role in influencing symmetry during embryonic development revealed

In this week's journal Nature, scientists at the Salk Institute for Biological Studies report that they have solved one of the "holy grail" puzzles of developmental biology: the existence of a mechanism that insures that the exterior of our bodies is symmetrical while inner organs are arranged asymmetrically.

11 May 2005

Research offers new molecular approaches to therapies for the most deadly cancers

Researchers at Wake Forest University Baptist Medical Center have found promising new molecular targets and treatment approaches for some of the most malignant brain tumors.

10 May 2005

Many lives may be saved by new blood test for ovarian cancer

A new blood test which has the potential to save many lives has been developed to detect ovarian cancer, a disease known as the silent killer because it is so difficult to identify.

9 May 2005

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

The first study identified a protein that seems to control the malignant features of brain tumor cells, suggesting a new treatment target for anti-cancer drugs. Researchers found that a little-known protein called Fra-1 was effective in controlling vascular endothelial growth factor D, a factor that promotes the growth of new blood vessels in most malignant brain tumors.

8 May 2005

GM mice live longer and give hope for anti-aging treatments

U.S. scientists have produced genetically modified mice that live 20 per cent longer than normal and may have possibly discovered an approach to extending the human lifespan.

8 May 2005

Scientists extend the lifespan of mice

Scientists at the University of Washington and their colleagues at other research centers have found a way to significantly extend the lifespan of mice while reducing the impact of the aging process. Their study, which will be published online by the journal Science on May 5, lends more credence to the free-radical theory of aging.

5 May 2005

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Patients with advanced non–small-cell lung cancer (NSCLC) whose tumor cells contain extra copies of the epidermal growth factor receptor (EGFR) gene may be more likely to respond to the drug gefitinib (Iressa), and this high gene copy number may be an effective predictor of gefitinib efficacy, according to a new study in the May 4 issue of the Journal of the National Cancer Institute.

3 May 2005

Gene variant that increases colon cancer risk

A paper published in this week's Journal of Clinical Oncology says Transforming Growth Factor Beta Receptor 1*6A (TGFBR1*6A) - a mutated gene present in nearly one in eight people and the most commonly inherited cancer susceptibility gene identified so far - might be responsible for a significant proportion of familial colorectal cancers.

2 May 2005

Growth Factor News and Research

Suppression of growth hormone and related compounds beginning in early adulthood may delay the onset or progression of several types of cancer

Chemo combo increases breast cancer survival

New approach to inhibiting blood vessel growth or angiogenesis

Cetuximab (Erbitux) can battle cancer and prolong life in many patients with advanced colorectal cancer

New drug combination prevents breast cancer growth pre-surgery

Gefitinib (Iressa) could reduce the size of breast cancer tumours

Engineers have found a way to modify a plastic to anchor molecules that promote nerve regeneration, blood vessel growth or other biological processes

SU11248 drug show promise against neuroendocrine tumors-stubborn cancers that respond poorly to chemotherapy

Bevacizumab (Avastin) combined with low-dose chemotherapy slows ovarian cancer

Moderate recreational and work-related physical activity may reduce the risk of ovarian cancer

Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patients

New anticancer drug SU11248 shows continued response for patients with late-stage kidney cancer

Vitamin A's paradoxical role in influencing symmetry during embryonic development revealed

Research offers new molecular approaches to therapies for the most deadly cancers

Many lives may be saved by new blood test for ovarian cancer

Promising new molecular targets and treatment approaches for some of the most malignant brain tumors

GM mice live longer and give hope for anti-aging treatments

Scientists extend the lifespan of mice

Study identifies possible marker for efficacy of gefitinib in lung cancer patients

Gene variant that increases colon cancer risk

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News